Brief: Bioxytran’s Oral Antiviral Drug To Enter Dose Optimization Clinical Trial For Covid-19
21/02/2024 14:18
Feb 21 (Reuters) - Bioxytran Inc BIXT.PK :
* BIOXYTRAN’S ORAL ANTIVIRAL DRUG TO ENTER DOSE OPTIMIZATION
CLINICAL TRIAL FOR COVID-19
Source text for Eikon: ID:nGNX4CMBTm
Further company coverage: BIXT.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Bioxytran
See all newsUS officials pressed China on rare earths, farm goods commitments, Bessent says (updated)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst (updated)
Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst
Brief: Bioxytran Inc Reports Positive Phase 1B/2A Clinical Study Results For Prolectin-M, Broad-Range Antiviral Drug In Mild To Moderate Covid-19
Brief: Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance With Prolectin-Mbioxytran